Celltrion announced that they received the final analysis of additional clinical results of Remsima from Contract Research Organization for its applying for U.S. approval
On July 21, Celltrion announced that they received the final analysis of additional clinical results of Remsima from Contract Research Organization for its applying for U.S. approval.
Celltrion plans to apply for sale approval of Remsima to U.S. Food and Drug Administration soon on the basis of ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
